Heterozygous FNIP1/homozygous FNIP2 double knockout mice developed renal cancer at 24 months, akin to heterozygous FLCN knockout mouse models, thereby reinforcing the significance of FNIP1 and Fnip2 in tumor suppression and suggesting potential molecular targets for novel renal cancer therapies (Hasumi et al., 2016; Mo et al., 2019). The gene discussed is FLCN; the disease is neoplasm.